GlassScriptPhysician profile
Berj M Nercessian
NPI 1093705329
$10,957.22
in general payments reported to CMS, 2019-2025
28 companies · $2,112 in 2025
The $2,112 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,140 · 2020: $1,103 · 2021: $997 · 2022: $1,488 · 2023: $1,859 · 2024: $2,258 · 2025: $2,112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,870 · Education: $359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,870.04 |
| Education | $358.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,266.92 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Abbvie INC. | $1,332.67 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,150.58 | 2019-2025 | |
| Ucb, INC. | $1,146.59 | 2019-2025 | Cimzia, Bimzelx |
| Amgen INC. | $851.20 | 2019-2025 | Tavneos, Enbrel, Otezla |
| Pfizer INC. | $749.95 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $662.93 | 2020-2025 | Orencia |
| Glaxosmithkline, LLC. | $461.03 | 2019-2025 | Benlysta |
| Fresenius Kabi USA, LLC | $351.03 | 2023-2025 | Idacio, Tyenne |
| Lilly USA, LLC | $315.90 | 2019-2022 | |
| Organon LLC | $270.96 | 2021-2025 | Renflexis, Hadlima |
| Genzyme Corporation | $198.90 | 2024-2025 | |
| Genentech USA, INC. | $169.46 | 2019-2025 | Actemra |
| Horizon Therapeutics Plc | $157.41 | 2021-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $136.95 | 2022-2025 | Saphnelo |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $115.17 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.99 | 2020-2024 | Cyltezo |
| Mallinckrodt Hospital Products INC. | $86.91 | 2024 | Acthar |
| Sandoz INC. | $84.05 | 2023-2024 | Hyrimoz |
| Merck Sharp & Dohme LLC | $57.64 | 2019-2020 | |
| Hikma Pharmaceuticals USA | $54.12 | 2019-2021 | |
| Celgene Corporation | $53.28 | 2019 | |
| Acella Pharmaceuticals, LLC | $39.99 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $38.05 | 2019 | |
| Aurinia Pharma U.S., INC. | $36.56 | 2025 | Lupkynis |
| Mylan Institutional INC. | $33.59 | 2023 | Hulio |
| Actelion Pharmaceuticals US, INC. | $30.13 | 2024 | Opsumit |
| Sebela Pharmaceuticals INC. | $16.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Berj Nercessian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.